BridgeBio Pharma BBIO Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's intangibles (net)?
- BridgeBio Pharma (BBIO) reported intangibles (net) of $27.36M in Q1 2026.
- How has BridgeBio Pharma's intangibles (net) changed year-over-year?
- BridgeBio Pharma's intangibles (net) decreased by 1.6% year-over-year, from $27.8M to $27.36M.
- What does intangibles (net) mean?
- The net value of non-physical assets like patents, licenses, and intellectual property.
- How do you interpret intangibles (net)?
- An increase typically reflects successful acquisitions of new drug candidates or technologies, while a decrease indicates amortization or impairment.
- How does intangibles (net) compare across companies?
- Highly variable depending on the company's strategy of internal R&D versus external acquisition of assets.